만성 정신분열병 환자에서 Risperidone과 Clozapine이 체중과 혈당에 미치는 영향
The Influences of Risperidone and Clozapine on Body Weight and Glucose Level in Patients with Chronic Schizophrenia
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
본 연구는 비전형적 항정신병약물이 체중과 혈당에 미치는 영향을 알아보고 그에 관계되는 여러 변인들의 관련성을 알아보고자 하였으며 이를 위해 비전형적 항정신병약물인 risperi done과 clozapine을 쓰는 환자 각 20명, 대조군으로 전형적 항정신병약물인 haloperidol을 쓰는 환자 20명을 대상으로 입원 후 4주, 8주, 12주째 체중과 공복 시 혈당을 입원 초기 체중 및 혈당과 비교하였으며 각 약물군 간의 차이를 조사하여 다음과 같은 결과를 얻었다. 첫째, 연구 대상 환자의 초기 특성 상 clozapine군이 ha-loperidol과 risperidone군에 비하여 입원 시 체중이 높은 상태였는데 이는 clozapine을 복용하는 환자들이 이전에 haloperidol과 risperidone을 포함한 여러 가지 항정신병약물을 복용했던 경험이 있고 이로 인해 이미 어느 정도의 체중 증가 있었던 것으로 생각해볼 수 있다. 둘째, 체중 변화는 risperi done과 clozapine군 모두 ha-loperidol을 쓴 군과 유의한 차이가 없었다. 셋째, 혈당 변화도 비전형적 항정신병약물인 risperidone과 clozapine군이 haloperidol군에 비해 의미 있는 차이가 없었다. 넷째, 몇 가지 변수들이 체중과 혈당의 변화에 연관성을 가지고 있었으나 그 정도는 크지 않았고 그 인과관계를 증명할 수는 없었다. 위의 결과들에서 볼 때 유병 기간이 길고 이전에 여러 가지 항정신병약물을 복용한 경험이 있는 환자, 약물 복용에 따른 증상의 호전 정도가 두드러지지 않는 만성적인 정신분열병 환자들에서는 비전형적 항정신병약물이 전형적 항정신병약물에 비해 체중 변화와 혈당의 수치를 변화시키는 경향이 크지 않다는 점을 알 수 있었다.
Abstract
The goal of this study was to examine the changes in body weight and glucose levels of the patients treated with risperidone, clozapine or haloperidol in order to compare the effect of risperidone or clozapine with that of haloperidol. Methods：For nine months(January to September, 2003), a prospective study was performed in 60 patients with chronic schizophrenia who were in Seoul National Hospital. Two-week period was required for a drug wash-out. The patients were randomly assigned to risperidone, clozapine and haloperidol groups. They were given risperidone(n=20), clozapine(n=20) and haloperidol(n=20), respectively, everyday for 12 weeks. To examine the effects of these drugs on body weight and fasting glucose levels, we measured body weight and glucose levels of all the patients first without the drug treatment and at each end of 4, 8, and 12-week periods with the treatment. And we examined the differences among three groups in the changes of body weight and fasting glucose levels. Results：There were no significant differences in the changes of the body weight and fasting glucose levels between the atypical antipsychotics(risperidone or clozapine) and the typical antipsychotics(haloperidol). Conclusion：The study in the patients with chronic schizophrenia suggests that risperidone or clozapine do not cause any additional effects on body weight or glucose levels compared to haloperidol.
참고문헌 (29)
- McGrath J, "Treatment of schizophrenia", 319, pp.1045~1048 (1999)
- Allison DB,, "Antipsychotic-inducedweight gain: a comprehensive research synthesis.", 156, pp.1686~1696 (1999)
- Am JPsychiatry, "NHLBI obesity education initiative expertpanel on the identification,evaluation and treatmentof overweight and obesity in adults:the evidence report", 6, pp.51~209 (1998)
- Kurzthaler I,, "The clinical implicationsof weight gain in schizophrenia", 62, pp.32~37 (2001)
- Wetterling T, "Body weight gain with atypical antipsychotics: a comparison of weight gain liabilities", 60, pp.358~363 (1999)
- Bustillo JR,, "Differentialeffect of clozapine on weight: a controlled study", 153, pp.817~819 (1996)
- Kraus T,, "Body weight and leptin plasma levels duringtreatment with antipsychotic drugs", 156, pp.312~314 (1999)
- Spivak B,, "The effect of long-term antipsychotic treatmenton the body weight of patients suffering from chronicschizophrenia: clozapine versus classical antipsychoticagents", 14, pp.229~232 (1999)
- 박혜상, "비전형적 항정신병 약물에서의 체중 증가", 11, pp.335~342 (2000)
- Dixon L,, "Prevalence and correlatesof diabetes in national schizophrenia samples", 26, pp.903~912 (2000)
- Hiles BW, "Hyperglycemia and glycosuria following chlorpromazinetherapy"
- Lindenmayer JP,, "Hyperglycemiaassociated with the use of atypical antipsychotics", 62, pp.30~37 (2001)
- 황재승,, "항정신병약물과 혈당조절이상", 10, pp.107~115 (2000)
- Wetterling T,, "Weight gain: side effect ofatypical neuroleptics?", 19, pp.316~321 (1999)
- Wirshing DA,, "Novel antipsychotics:comparison of weight gain liabilities", 60, pp.358~363 (1999)
- Csernansky J,, "Risperidone vs haloperidolfor prevention of relapse in schizophrenia and schizoaffectivedisorders:a long term double blind comparison", 9, pp.268~ (1999)
- Hummer M,, "Weight gain induced byclozapine.", 5, pp.437~440 (1995)
- Henderson DC, "Atypical antipsychotic-induced diabetesmellitus:how strong is the evidence?", 16, pp.77~89 (2002)
- Newcomer JW,, "Abnormalities in glucoseregulation during antipsychotic treatment of schizophrenia", 59, pp.337~345 (2002)
- Selke G,, "Atypical antipsychotic-induced differencesin glucose regulation in schizophrenia independent ofdifferences in adiposity", 26, pp.275~ (2000)
- Newcomer JW,, "Glucose metabolismduring antipsychotic treatment in schizophrenia", 49, pp.288~ (2001)
- Hagg S,, "Prevalence of diabetes and impaired glucosetolerance in patients treated with clozapine comparedwith patients treated with conventional depot neurolepticmedications.", 59, pp.294~299 (1998)
- Wirshing DA,, "Nonextrapyramidalside effects of novel antipsychotics of novel antipsychotics", 13, pp.45~50 (2000)
- , 2000, 369~370
- Haupt DW, "Risperidone-associated diabeticketoacidosis", 42, pp.279~280 (2001)
- American Diabetes Association., "Report of the ExpertCommittee on the Diagnosis and Classification of DiabetesMellitus", 24, pp.1~ (2001)
- , 2001, 351~353
- Smith RC,, "Hyperglycemiain schizophrenic patients with olanzapine and clozapine.In: New Research Abstracts of the 154th AnnualMeeting of the American Psychiatric Association", 321, pp.87~ (2001), New Orleans, La. Abstract NR
- Allison DB,, "Random bloodglucose levels in patients with schizophrenia treated withtypical and atypical antipsychotic agents an analysis ofdata from double-blind randomized, controlled clinicaltrial", 11, pp.280~ (2001)